"High clinical suspicion is important for this population of patients. Since muscular dystrophy is progressive in nature, monitoring disease progression in these patients is critical for timing ...
EVRY, France--(BUSINESS WIRE)--Atamyo Therapeutics, a biotechnology company focused on the development of new-generation gene therapies targeting muscular dystrophies and cardiomyopathies, today ...
ETHealthworld.com brings latest muscular dystrophy news, views and updates from all top sources for the Indian Health ...
RESEARCH TRIANGLE PARK, N.C. , Aug. 3, 2023 /PRNewswire/ -- Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, ...
PALO ALTO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced ...
A study by Indiana University School of Medicine researchers sheds new light on the development and treatment of a rare form of muscular dystrophy. The study's findings were recently published in ...
Myotonic dystrophy type 1 (DM1) is a genetic disease characterized by progressive muscular weakness. There is currently no treatment despite many recent efforts. But now researchers from Japan may ...
Data are scarce regarding the benefits of strength training for muscular dystrophies, for which there are no cures. Strength training to ameliorate the effects of muscular dystrophies (MDs) was found ...
BridgeBio Pharma, Inc. announced it will host an investor webinar on July 11, 2025, at 8:00 am ET, featuring Dr. Matthew Wicklund from the University of Texas Health Science Center. The webinar will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results